Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
Armstrong
Paul W
PW
Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. paul.armstrong@ualberta.ca
Adams
Peter X
PX
Al-Khalidi
Hussein R
HR
Hamm
Christian
C
Holmes
David
D
O'Neill
William
W
Todaro
Thomas G
TG
Vahanian
Alec
A
Van de Werf
Frans
F
Granger
Christopher B
CB
D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D006333:Heart Failure / Q000517:prevention & control; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D015337:Multicenter Studies as Topic / Q000379:methods; D009203:Myocardial Infarction / Q000401:mortality / Q000628:therapy*; D011292:Premedication; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D012107:Research Design; D012770:Shock, Cardiogenic / Q000517:prevention & control; D057127:Single-Chain Antibodies; D015996:Survival Rate
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D057127:Single-Chain Antibodies; C402724:pexelizumab